Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Polvino

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Reproductive Medicine|June 1, 1992
Prospects for human gene therapyE M Karson, W Polvino, W F Anderson
Diabetes Technology & Therapeutics|July 28, 2001
Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetesP Strange, S L Schwartz, R J Graf, et al.
American Journal of Hypertension|October 6, 1999
Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effectsA A Taylor, A M Shepherd, W Polvino, et al.
The Journal of Clinical Endocrinology and Metabolism|February 19, 1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditureJ Svensson, L Lönn, J O Jansson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 14, 1998
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young malesJ Svensson, C Ohlsson, J O Jansson, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Reproductive Medicine|June 1, 1992
Prospects for human gene therapyE M Karson, W Polvino, W F Anderson
Diabetes Technology & Therapeutics|July 28, 2001
Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetesP Strange, S L Schwartz, R J Graf, et al.
American Journal of Hypertension|October 6, 1999
Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effectsA A Taylor, A M Shepherd, W Polvino, et al.
The Journal of Clinical Endocrinology and Metabolism|February 19, 1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditureJ Svensson, L Lönn, J O Jansson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 14, 1998
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young malesJ Svensson, C Ohlsson, J O Jansson, et al.
Pageof 1